Enoumena Therapeutics
Company
Enoumena Therapeutics develops one asset, approved (landiolol in supraventricular tachycardia). Mostly small molecule acting on ADRB1.
- 1
- Asset
- Furthest stage
- Approved
- 0
- Trials
- 1
- Signal
Pipeline
1Selectively blocks beta-1 adrenergic receptors to rapidly reduce ventricular rate.
Approved, Small molecule, ADRB1, supraventricular tachycardia, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals1
- Similar companies1